Opioid Use in Pregnancy: Risks to Mother & Baby

Opioid exposure during pregnancy poses significant risks; however, untreated opioid use disorder (OUD) also harms mother and fetus. Medication-assisted treatment (MAT) is standard of care.

Maternal Risks

  • Overdose, infections (endocarditis, abscesses), poor prenatal care engagement.
  • Obstetric complications: placental abruption, preeclampsia, preterm labor, fetal growth restriction.
  • Psychiatric comorbidity (depression, anxiety, PTSD).

Fetal/Neonatal Risks

  • Neonatal Abstinence Syndrome (NAS) / NOWS: 50–80% of opioid-exposed infants. Irritability, hypertonia, tremors, poor feeding, diarrhea, seizures. Onset 24–72 hrs (short-acting) to 5–7 days (methadone/buprenorphine). Scored by Finnegan/Eat-Sleep-Console.
  • Preterm birth, low birth weight, small for gestational age.
  • Congenital malformations: conflicting data; possible ↑ neural tube defects, cardiac defects (codeine/oxycodone early pregnancy).
  • Neurodevelopmental: subtle cognitive/behavioral differences; confounded by environment.

Standard of Care: Medication-Assisted Treatment (MAT)

  • Methadone or Buprenorphine (monotherapy preferred over buprenorphine/naloxone) – stabilize, reduce illicit use, improve prenatal engagement.
  • Do not detoxify during pregnancy (high relapse, fetal stress).
  • Multidisciplinary: OB, addiction medicine, pediatrics, social work.

Breastfeeding

Encouraged on stable MAT (low milk levels); contraindicated if active illicit use or HIV.

Compassionate, non-punitive care improves outcomes for dyad.

Substance Abuse - Related Articles